Nachrichten zur Intellia Therapeutics Inc. Aktie

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice

Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Lets find…

Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet

The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that…

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

Intellias (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline....…

Intellia jumps 13% after Q1 updates

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023.…

Form 8-K Intellia Therapeutics, For: May 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Form 8-K Intellia Therapeutics, For: Apr 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia up 12% as Canaccord starts with Buy citing gene editing approach

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Intellia Therapeutics, For: Mar 23

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary Angioedema

Intellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary Angioedema...…

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia gains as BMO upgrades citing recent weakness

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Intellia Therapeutics Stock Jumped This Week

Intellia Therapeutics landed a historic regulatory nod from the FDA....…

Intellia (NTLA) Stock Surges After Crispr Gene Editing Therapy Gets ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia shares jump as gene therapy trial gets U.S. regulator nod

...(Reuters) - Shares of gene editing firm Intellia Therapeutics......…

Intellia’s stock jumps as CRISPR therapy moves into Phase 2 clinical trial

Shares of Intellia Therapeutics Inc. NTLA rallied about 10% in premarket trading on Thursday after the company said the Food…

Form 8-K Intellia Therapeutics, For: Mar 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia stock rises on FDA nod to start trial of CRISPR gene editing therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022.…

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing…

Better Buy: Beam Therapeutics or Intellia Therapeutics?

The two clinical-stage gene-editing companies have good long-term prospects....…

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its…

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics upgraded at Citi after recent selloff

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?

The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that…

Intellia awarded innovation passport in UK for genetic disorder treatment

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Intellia Therapeutics im Wert von 93.323$

Sepp-Lorenzino, Laura - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Intellia Therapeutics im Wert von 89.659$

Sepp-Lorenzino, Laura - Vorstand - Tag der Transaktion: 2023-01-05...…

Insiderhandel: EVP, Chief Business Officer verkauft Aktien von Intellia Therapeutics im Wert von 67.425$

Hicks, Derek - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: President and CEO verkauft Aktien von Intellia Therapeutics im Wert von 248.302$

Leonard, John M. - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Intellia Therapeutics im Wert von 95.779$

Lebwohl, David - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 62.959$

Clark, Eliana - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Intellia Therapeutics im Wert von 90.309$

Goddard, Glenn - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 7.965$

Clark, Eliana - Vorstand - Tag der Transaktion: 2023-01-03...…

Insiderhandel: EVP, General Counsel verkauft Aktien von Intellia Therapeutics im Wert von 42.345$

Basta, James - Vorstand - Tag der Transaktion: 2023-01-04...…

Form 8-K Intellia Therapeutics, For: Jan 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?

Intellia Therapeutics stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of…

Form 8-K Intellia Therapeutics, For: Nov 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Shares Drop 11% After Public Offering Prices

Intellia Therapeutics Shares Drop 11% After Public Offering Prices...…

Intellia therapeutics dips on pricing of public offering of common stock

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics announces $250 public offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%

  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics…